Terns Pharmaceuticals, Inc.
NNASDAQ:TERNShare Statistics
As of December 31, 2025, Terns Pharmaceuticals, Inc. has 112.32M shares outstanding.
| Shares Outstanding | 112.32M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | -7.15 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | -45.02 |
| P/OCF Ratio | -45.02 |
Financial Position
As of December 31, 2025, Terns Pharmaceuticals, Inc. maintains a current ratio of 62.41, meaning it holds 62.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 62.41 |
| Quick Ratio | 62.09 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.01 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -13.85, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -13.85 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -2.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.10, meaning Terns Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -20.10 |
| FCF Yield | -2.22 |
Scores
As of December 31, 2025, Terns Pharmaceuticals, Inc. has an Altman Z-Score of 119.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 119.77 |